Consumers in China are taking to social media to express their support for Huawei as the U.S. government looks to ramp up pressure on the Chinese smartphone maker.Technologyread more
U.S. President Donald Trump's latest tariff increase — and Beijing's plans to counter them — are hitting U.S. companies in China, according to a joint survey this month by...China Economyread more
"We are also constantly watching whether the trade war will turn into a tech war," Ma said Tuesday, according to a CNBC translation of his Chinese remarks published by a locak...China Economyread more
TransferWise, the money transfer start-up, was valued at $3.5 billion after investors bought $292 million of shares in a secondary sale.Technologyread more
Kohl's, J.C. Penney and Nordstrom release disappointing earnings news, putting a damper on their sector.Retailread more
Bezos's comments give a rare glimpse into his interest in the auto industry. Amazon recently invested in two self-driving start-ups.Technologyread more
While investing often seems like a contrarian game where going against the flow feels like the better bet, the reality is that investors who bought the most-favored stocks...Hedge Fundsread more
The economist thinks the Fed ought to pay more attention to financial markets when setting interest rates.The Fedread more
U.S. Trade Representative Robert Lighthizer will meet with officials from the European Union and Japan at the ministerial meeting of the Organization for Economic Co-operation...World Economyread more
Talks between the world's two largest economies have stalled after each nation lobbied higher tariffs on the other's imports.Traderead more
"Pretty much the entire suite of apps that 'talk' over the internet could be vulnerable," said Tom Uren, a senior analyst at the Australian Strategic Policy Institute's...Cybersecurityread more
If pros must buy health care, Cramer thinks they'll take a long hard look at this stock.
It's BioMarin Pharmaceutical.
Shares have surged a whopping 54% year to date, and Cramer thinks those gains will catch the attention of money managers; especially those looking to spruce up their portfolios with winners.
"They'll buy if only so that they can tell their clients, 'yeah, we own it, we're geniuses,'" Cramer said.
However, if they were to look at the business fundamentals, those money managers may like the stock for other reasons entirely.
As a cutting edge drugmaker, BioMarin Pharma is aggressively developing enzyme replacement therapies for rare genetic disorders that would otherwise go untreated.
"BioMarin has four drugs currently on the market: two of them treat a condition called MPS that causes horrific damage at a cellular level if left untreated, another one helps manage phenylketonuria or PKU, which can cause severe developmental problems and neurological issues, and BioMarin's fourth drug treats a rare autoimmune disorder that causes muscle weakness," Cramer explained.
Because all are orphan drugs they generate significant revenue; anywhere from $95,000 to $350,000 per patient per year. And Cramer says all the drugs have room to grow.
In addition, Cramer likes the pipeline potential.
"BioMarin currently has a terrific late-stage pipeline, with an enzyme replacement drug for another type of MPS that could be approved by the FDA in the first quarter of next year and might do $650 million in peak sales, Also, it has two more orphan drugs that are either in or about to start phase 3 development, including a treatment for Pompe disease, an often fatal disorder that disables the heart and skeletal muscles. If approved, it could generate $500 million in peak sales. "
In addition, Cramer added the company is working on a potentially revolutionary treatment for breast and ovarian cancer that disrupts the DNA of tumor cells. "That could be a billion dollar drug," he said.
All told, Cramer sees plenty of fundamental reasons for the stock to rally. But that's not all. There are bullish chart patterns too.
Read More from Mad Money with Jim Cramer
5 buys as pros puff up protfolios
Cramer: International Paper 'ludicrously' cheap
Cramer's stock with serious upside potential
According to technical analysis from Cramer colleague Bob Lang, the founder and senior strategist at ExplosiveOptions.net, BioMarin's chart is red hot. The stock recently broke out above its $66 ceiling of resistance on strong volume. Lang believes that's a significant buy signal.
Considering the technicals are positive, the fundamentals are positive and the practice of window dressing could buoy shares, even up 54% ytd, Cramer thinks Biomarin should have more room to run.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the "Mad Money" website? firstname.lastname@example.org